The Additive of Latanoprost 0.005% in Patients with Maximum Tolerated Medical Therapy Regimen.

Kook, Michael Scott; Sung, Kyung Rim

Original Article

Journal of the Korean Ophthalmological Society 1999;40(2):505-512.
Published online February 1, 1999.

The Additive of Latanoprost 0.005% in Patients with Maximum Tolerated Medical Therapy Regimen.

Michael Scott Kook, Kyung Rim Sung

Department of Ophthalmology, College of Medicine, University of Ulsan, Asan Medical Center.

난치성 녹내장 환자에서 Latanoprost 0.005% 병용 요법의 효과

국문석(Michael Scott Kook),성경림(Kyung Rim Sung)

Abstract

Latanoprost 0.005% which is a currently available ocular hypotensive agent has been known to produce an additional reduction of intraocular pressure when used in combination with beta adrenergic bloker. The aim of this study was to evaluate the additive effect of this drug in patients with maximum tolerated medical therapy regimen. 48 eyes of 32 patients were categorized into 2 groups as to their type of glaucomas(primary open abgle glaucoma(POAG) vs chronic angle closure glauoma(CACG), and pilocarpine use. POAG group showed 22.3, 24.8, 22.7, 21.0, 21.4% and CACG group showed 17.6, 17.1, 15.7, 17.5, 17.8% of ocular hypotensive effect at post treatment 2 weeks, 4 weeks, 3 months, 6 months, 9 to 12 months, respectively and there was no satistically significant difference between two groups. Pilocarpine using group showed 25.5, 30.5, 26.4, 23.4, 17.8% and non-using group showed 20.6, 18.9, 19.0, 18.7, 25.1% of ocular hypotensive effect at each follow up period. Conclusively, latanoprost 0.005% appeared to be a very effective drug in reducing intraocular pressure in patients with maximum tolerated medical therapy regimen without regard to their type of glaucomas, and use of parasympathomimetics.

Key Words: Latanoprost;Pilocarpine;POAG;CACG